Westhoff U, Grosse-Wilde H
Institute of Immunology, University Hospital of Essen, Germany.
Vox Sang. 1995;68(2):73-6. doi: 10.1111/j.1423-0410.1995.tb02556.x.
Soluble HLA class I (sHLA-CI) and class II (sHLA-CII) molecules were quantitated in 11 commercially available factor VIII and prothrombin complex concentrate (PCC) preparations by enzyme-linked immunosorbent assays (ELISA). In 4 preparations, we detected traces of sHLA-CI (0.01-0.07 mg/l), and in 7 hemostatic preparations small amounts of sHLA-CII molecules (0.02-0.28 mg/l). The concentrations of these contaminant molecules are unequivocally below the mean values of sHLA in human plasma (sHLA-CI: 1.01 +/- 0.72 mg/l; sHLA-CII: 1.53 +/- 2.44 mg/l). Based on the total amount of chronically administered factor VIII or PCC, contaminating sHLA molecules may be in principle able to exert immunomodulatory effects in patients treated with such preparations.
通过酶联免疫吸附测定(ELISA)对11种市售的凝血因子VIII和凝血酶原复合物浓缩剂(PCC)制剂中的可溶性HLA I类(sHLA-CI)和II类(sHLA-CII)分子进行了定量分析。在4种制剂中,我们检测到了痕量的sHLA-CI(0.01 - 0.07毫克/升),而在7种止血制剂中检测到了少量的sHLA-CII分子(0.02 - 0.28毫克/升)。这些污染物分子的浓度明显低于人血浆中sHLA的平均值(sHLA-CI:1.01±0.72毫克/升;sHLA-CII:1.53±2.44毫克/升)。基于长期给予的凝血因子VIII或PCC的总量,污染的sHLA分子原则上可能会对接受此类制剂治疗的患者产生免疫调节作用。